Muscle Invasive Bladder Cancer clinical trials

Explore recruiting muscle invasive bladder cancer clinical trials.

Recruiting muscle invasive bladder cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Muscle Invasive Bladder Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery

Czechia

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)

Italy, Denmark, Poland, Ireland, Sweden, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

Netherlands, Spain, Romania, Poland, Latvia, Czechia +5 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Muscle Invasive Bladder Cancer trials by city

Muscle Invasive Bladder Cancer in Toronto Muscle Invasive Bladder Cancer in Vancouver Muscle Invasive Bladder Cancer in Montreal Muscle Invasive Bladder Cancer in Calgary Muscle Invasive Bladder Cancer in Edmonton Muscle Invasive Bladder Cancer in Ottawa Muscle Invasive Bladder Cancer in Winnipeg Muscle Invasive Bladder Cancer in Quebec City Muscle Invasive Bladder Cancer in Hamilton Muscle Invasive Bladder Cancer in Kitchener Muscle Invasive Bladder Cancer in London Muscle Invasive Bladder Cancer in Halifax Muscle Invasive Bladder Cancer in New York Muscle Invasive Bladder Cancer in Los Angeles Muscle Invasive Bladder Cancer in Chicago Muscle Invasive Bladder Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease